ISSCA Founder and President Daeyong Kim, Ph.D., announces plans to host the Regenerative Medicine Cell Therapies Symposium in Seoul, Korea in November.

MIAMI, April 2, 2018—International Association for Stem Cell Application (ISSCA) President Daeyong Kim, Ph.D., has announced plans to host Applications of Cell Therapies in Medicine and Aesthetic Surgery, a regenerative medicine symposium, in Seoul Korea November 24, 2018.

The symposium will be ISSCA’s principal event for 2018, during which the organization will launch its entire 2019 program, including stem cell certification courses for physicians to be held in locations worldwide, as well as the 2019 regenerative medicine symposium agenda.

In 2019, ISSCA plans to expand its activities to Asia by hosting at least one regenerative medicine symposium and four stem cell certification courses during the year. The Korea symposium will be structured as a scientific meeting in which regenerative medicine practitioners share their clinical experience. ISSCA affiliate Global Stem Cells Group, and biomedical and leading lab equipment manufacturer N-Biotek will launch new technology for regenerative medicine practitioners.

The international symposium is part of ISSCA’s mission to support a paradigm shift in healthcare from traditional to regenerative medicine in the 21st Century and provide cutting-edge information on developments in all areas of stem cell research. The Buenos Aires event will host a group of renowned international speakers in the field of stem cell and regenerative medicine, who will offer a day of rigorous scientific discourse aimed at physicians.

Topics of focus at the symposium include:

  • Management of aging at the cellular level
  • Stem cell therapies in medical aesthetics: the latest methods of harvest and isolation Non-invasive protocols of non-surgical facial and body rejuvenation
  • Beyond fillers and toxins
  • Combined treatment plans that include surgical methods for the management of advanced aging
  • Restoration and assisted hair transplantation with biomaterials and growth factors
  • The invaluable role of biological cosmeceutical in the management of aging
  • The aging process from the inside out: the role of hormones
  • Management of the latest digital marketing tools for recruiting patients in their aesthetic clinics

The symposium will incorporate the biology, medicine, applications, regulations, product development, and commercialization of stem cells. Business opportunities, challenges, and potential strategies for overcoming these challenges will also be addressed.

To learn more about the ISSCA Korea symposium and to make a reservation, visit the stemcellconference.org website, email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training. and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

 ISSCA Korea regenerative medicine symposium

Daeyong Kim, Ph.D., and Syed Salman Naeem Gilani, M.D.

 

 

 

 

 

 

 

ISSCA Istanbul conference: The International Association for Stem Cell Application (ISSCA) has announced plans to host a regenerative medicine symposium at the Hotel Hyatt Regency in Istanbul, Turkey April 28, 2018.

MIAMI, Feb 19, 2018—The International Association for Stem Cell Application (ISSCA) will host its next regenerative medicine symposium at the Hotel Hyatt Regency in Istanbul, Turkey April 28, 2018.

The symposium agenda will focus on:

  • Molecular biology
  • Clinical advances in stem cell research
  • Models of treatment in surgical and cosmetic applications, and in clinical conditions
  • Technological advances
  • Application of minimally manipulated stem cells in the physician’s office
  • Stem cells, regenerative medicine and its application in anti-aging medicine, Pain Management and Orthopedics
  • Medical legal issues.
  • Regulatory Pathways

Istanbul, the economic, cultural, and historic center of Turkey, is the country’s most populous city. The luxurious Hotel Hyatt Regency, located near Istanbul’s Ataturk Airport, offers visitors the combination of comfort, culture, and convenience for exploring the ancient city. Symposium attendees will be able to discover sights such as the Blue Mosque and the Hagia Sophia.

The Istanbul international symposium is part of ISSCA’s mission to support a paradigm shift from traditional healthcare solutions to regenerative medicine, and provide the latest innovative discoveries and developments in all areas of stem cell research. The symposium will host a group of renowned international speakers, experts in the field of stem cell and regenerative medicine, who will provide a full day of rigorous scientific discourse directed to physicians.

The day’s events will incorporate information on stem cell biology, medicine, applications, regulations, product development, and commercialization, business opportunities, challenges, and potential strategies for overcoming those challenges.

To participate in the ISSCA Istanbul Symposium, reserve your spot by registering today.

For more information, visit the stemcellconference.org website, email info@stemcellsgroup.com, or call +1305 560 5337.

About International Society for Stem Cells Applications

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

###

ISSCA Istanbul conference

 

ISSCA Barcelona Symposium

 

 

 

 

 

Image: Benito Novas

 

Global Stem Cells Group founder and CEO Benito Novas was recognized as a leader in regenerative medicine at the XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery and Obesity, Dec. 2, 2017, in Mexico City.

MIAMI, Dec. 22, 2017—Benito Novas, founder and CEO of Global Stem Cells Group (GSCG), earned recognition for his leadership in regenerative medicine at the XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery and Obesity, Dec. 2, 2017, in Mexico City.

Novas accepted the recognition, signed and presented to him by Congress President Rector Doctor Arturo Conde at the event, honoring him for helping thousands of physicians around the world bring regenerative medicine therapies to their clinical practices.

Novas provided training and equipment to physicians throughout South America, North America, Europe, Asia, and the Middle East through GSCG affiliate companies Stem Cell Training, Adimarket online regenerative medicine store, and Stem Cell Center Network (present in more than 30 cities globally).

Novas is a global entrepreneur, manager, and keynote speaker with expertise in the field of specialized marketing focused on biotechnology, life sciences, and healthcare development.

The philosophy that has driven him to launch and grow his companies is the desire for a perpetual flow of knowledge and innovation with regard to the role of stem cells in modern medicine.

“My aim is to accelerate the process of getting promising stem cell research and technology developed into treatments and therapies, and to make them readily available to benefit the health and well-being of a broad range of patients,” he says.

Using specialized marketing techniques focused on stem cells and their impact on the field of aesthetic surgery, Novas created a multi-company corporation based on his visionary approach to healthcare management and regenerative medicine.

To learn more about Global Stem Cells Group, visit the company website, email info@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global Stem Cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.

Benito Novas recognized

 

 

 

 

 

 

 

Adimarket, a subsidiary of Global Stem Cells Group, has announced an agreement with biotechnology company Alolotl Biologix to distribute biological products for regenerative medicine applications worldwide.

 MIAMI, Dec.21, 2017— Adimarket, a subsidiary of Global Stem Cells Group (GSCG), and its subsidiary has announced an agreement with Phoenix, Arizona-based Alolotl Biologix to distribute the biotechnology company’s products for regenerative medicine applications worldwide.

Alolotl Biologix focuses on research to optimize the use of human biologicals and to develop biological-related products to foster regeneration and healing for a range of conditions, including orthopedic impairments, wound care, pain management, ophthalmic, cardiovascular, cosmetic, and more.

Adimarket will make the following amniotic liquid products available to qualified practitioners through its online store www.adimarket.net:

AxoBioFluid® C Amniotic Allograft Cryopreserved Liquid, cryopreserved liquid allograft derived from the amniotic membrane that provides structural tissue to advance soft tissue repair, replacement, and reconstruction. Product details:

  • Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
  • Immune privileged with anti-inflammatory and anti-bacterial properties
  • A rich source of growth factors, proteins, cytokines, hyaluronic acid, and collagen scaffolds
  • Contains extracellular matrix components for cellular   attachment and proliferation
  • Cryopreserved for an extended shelf life

AxoBioFluid® physician benefits

  • Procedures are efficient and do not require special instrumentation.
    •  The use of AxoBioFluid® is billed as patient pays, which makes it a great alternative revenue source.
    •  A library of research papers to demonstrate efficacy degenerated tissue is provided.

AxoBioFluid® patient benefits

Relevant Conditions

AxoBioFluidâ C Amniotic Allograft Cryopreserved Liquid, cryopreserved liquid allograft derived from the amniotic membrane that provides structural tissue to advance soft tissue repair, replacement, and reconstruction. Product details:

  • Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
  • Immune privileged with anti-inflammatory and anti-bacterial properties
  • A rich source of growth factors, proteins, cytokines, hyaluronic acid, and collagen scaffolds
  • Contains extracellular matrix components for cellular   attachment and proliferation
  • Cryopreserved for an extended shelf life

AxoBioFluidâ physician benefits

  • Procedures are efficient and do not require special instrumentation.
    •  The use of AxoBioFluid® is billed as patient pays, which makes it a great alternative revenue source.
    •  A  library of research papers to demonstrate efficacy is provided.

AxoBioFluid® Amniotic Allograft Cryopreserved Liquid is a cryopreserved liquid allograft derived from the placental components of the amnion to advance soft tissue repair, replacement, and reconstruction. It is classified as minimally manipulated under FDA regulation 21 CFR Part 1271 and section 361 of the PHS. Benefits of AxoBioFluid® AxoBioFluid® is a human allograft fluid derived from the amniotic layer of the placenta. The two primary cell lines which reside in the amnion are human mesenchymal stromal cells (hMSC) and human amnion epithelial cells (hAEC). Both of these cells are considered to be pluripotent stem cells. AxoBioFluid® contains growth factors released while amniotic cells are grown in culture such as epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and transforming growth factor – beta (TGF-β). These proteins are essential for fetal growth and development and express significant therapeutic benefits when used as a treatment for various injuries and degenerative conditions. AxoBioFluid® is immuneprivileged, anti-inflammatory, anti-fibrotic, pro-vascular, and cytoprotective because of the cells being sourced from the amnion. These secreted factors also signal endogenous progenitor cells to promote regeneration and repair of damaged or degenerated tissue.

AxoBioFluid

  • Degenerative disorders such as osteoarthritis
    • Joint pain
    • Inflammatory conditions such as:
  • Bursitis
  • Tendonitis
  • Fasciitis
  • Epicondylitis
  • Soft tissue injuries such as:
  • Ligament & Tendon sprains
  • Muscle & Meniscus tears
  • Wound Care

AxoBioMembrane, a dehydrated allograft membrane patch derived from the amnion that advances wound repair, skin replacement, and reconstruction. Product details:

  • Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
  • Immune privileged with anti-inflammatory and anti-bacterial properties
  • Contains extracellular matrix components for cellular attachment and proliferation
  • Dehydrated and terminally e-beam sterilized for an extended shelf life.

AxoBioMembraneä Amniotic Allograft Membrane, like all allograft tissue products, has been subjected to recovery microbiological study and has been terminally sterilized with electron beam sterilization.  It works by forming fibrin-elastin bonds at the wound site, ensuring excellent wound adherence. This generates a barrier that protects exposed nerve endings from irritants, providing pain relief while creating a favorable environment for tissue repair and regeneration. In addition, the AxoBioMembrane™ prevents excessive moisture loss by creating a vapor barrier at the wound surface. Growth factors present in the membrane are released into the wound bed, promoting angiogenesis leading to new blood supply needed for cellular migration, proliferation and ultimately, wound repair. Infection is one of the biggest concerns with chronic wounds. AxoBioMembrane™ functions as a bacteriostatic agent, which can inhibit the growth of bacteria at the wound site and reduce the rate infection. It has also been reported to have anti-fibrotic properties, which can reduce scarring. The membrane contains glycoprtoteins found exclusively in the amnion. AxoBioMembrane™ lacks specific surface antigens, which make it immune-privileged and anti-inflammatory.

AxoBioMembraneä physician benefits

  • Procedures are efficient and do not require special instrumentation.
  • AxoBioMembrane™ is billed as patient pays, which makes it a great alternative revenue source.
  • We provide a library of research and white papers to demonstrate efficacy.

AxoBioMembraneä  patient benefits:

  • Pain Reduction
  • Wound Adherence
  • Less Scarring
  • Faster Healing
  • Neovascularization
  • Wound Barrier
  • Anti-bacterial
  • Immune Privileged

AxoBio products are available to purchase on the Adimarket Website.

For more information, visit the Adimarket regenerative medicine online store website, email info@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world. 


About Adimarket:

Adimarket, Inc.,
a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals.

Adimarket was founded to provide practitioners the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting-edge treatments.

About Alolotl Biologix:
amniotic biofluid
Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through research, technology and clinical application. Axolotl Biologix is expanding the human body’s ability to regenerate by developing and manufacturing regenerative human cell and tissue, medical technologies that are disrupting traditional, more invasive, painful, and expensive treatment protocols. For more information, visit www.axobio.com.

###

 

amniotic biofluid

Escazú, Costa Rica

 

 

 

 

Image: CIMA Hospital in Escazú

 

 

Global Stem Cells Group announces plans to expand its Stem Cell Center Network to include a new stem cell treatment center in Escazú, Costa Rica.

MIAMI, Dec. 21, 2017—Global Stem Cells Group (GSCG), a world leader in stem cell and regenerative medicine, has announced the opening of a new stem cell center in its Stem Cell Center Network in Escazú, Costa Rica. The new center will focus on treating patients who suffer from regenerative illnesses.

The new center, located at the CIMA Hospital in Escazú, will be headed by Leslie Mesen, M.D., a specialist in anti-aging medicine.

The new center is part of Global Stem Cells Group’s worldwide expansion of its clinical presence, partnering with qualified physicians experienced in stem cell therapies to open new clinics and utilize GSCG stem cell products and protocols inpatient treatments. GSCG has established similar alliances in 33 cities worldwide.

The new center’s location at the CIMA Hospital in Escazú offers a safe and luxurious venue for patients traveling from the U.S. and other countries for treatment.

Mesen studied medicine at the Ibero-American University (UNIBE) in San José, Costa Rica. He leads numerous regenerative medicine courses in the United States and throughout Latin America. He is board certified in anti-aging and regenerative medicine by The American Academy of Anti-Aging Medicine.

Mesen has served as chief medical officer of three highly-recognized anti-aging institutes, including the Costagenics Age Management program (2007-2010), Anti-Aging Institute of the Americas (2010-2013) and the Anti-Aging and Wellness Clinic (2014-present).

The new center in Escazú is equipped with the latest, cutting-edge regenerative medicine technology. Mesen was trained in Global Stem Cells Group facilities in the U.S.

“This new center, headed by Dr. Mesen, is a perfect reflection of Global Stem Cells Group’s commitment to meet the growing needs of clients and patients,” says GSCG founder and CEO Benito Novas. “Together with Dr. Mesen, we will continue to provide the latest medical technology and benefits available through our regenerative medicine products and protocols.

Global Stem Cells Group hopes to approve five more franchises in early 2108. If you are a pysician interested in learning more about joining the world’s largest regenerative medicine practitioner network please contact us www.stemcellcenter.net

GSCG provides stem cell treatments for a variety of conditions, diseases, and aesthetic treatments at facilities worldwide. The new facility will have an international staff experienced in administering the leading cellular therapies available.

Global Stem Cells Group’s Escazú clinic is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. GSCG clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.

GSCG is committed to providing the highest standards of services and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

To learn more about Global Stem Cells Group, visit the GSCG website,  email info@stemcellsgroup.com, or call +1305 560 533

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global Stem Cell Group’s aim is to be the largest recognized stem cell and regenerative medicine network in the world.

 

 

Escazú, Costa Rica.

Jornadas Mediteraneas

Global Stem Cells Group Research Director Martiza Novas Recognized for Her Work in Regenerative Medicine

MIAMI, Dec. 22, 2017—Maritza Novas Research Director, Global Stem Cells Group, earned recognition for her work and achievements in regenerative medicine at the XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery and Obesity, Dec. 2, 2017, in Mexico City.

Novas has been in the forefront of medical and anti-aging medicine since 2001. The recognition, signed and presented to her by Congress President Rector Doctor Arturo Conde at the event, honored her for 10 years of dedicated service educating others on clinical applications of stem cells.

A pioneer in the use of stem cells for therapeutic procedures, pain management, and treatment of chronic degenerative conditions, Novas has trained more than 2,000 physicians worldwide on procedures and protocols for harvesting and isolating adipose-derived stem cells for autologous re-implantation, and with problem-solving methods to improve patient outcomes.

Novas specializes in stem cell procedures for anti-aging applications, tissue regeneration, functional medicine, age management, bio-identical hormone therapy, and weight control. Novas has been a certified ISSCA specialist for more than four years.

As a member of Stem Cell Training, Inc.’s research and development team, Novas has assisted in the development of new proprietary adipose and bone marrow protocols currently being used in the company’s comprehensive stem cell training courses.

Novas earned a medical degree at the University of Havana, Cuba in 1993. Novas, Director of Research and Development for Global Stem Cells Group, has been in the forefront of medical and anti-aging medicine since 2001.

She has been a member of the American Academy of Anti-Aging Medicine since 2004 and draws upon 10 years of combined experience with therapeutic procedures, hormonal replacement and nutritional therapies, liposculpture, and fat transfers. Novas is currently completing a master’s degree in Molecular Biology at Lehigh University.

For more information, visit the Global Stem Cells Group website, email info@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global Stem Cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.

 

Maritza Novas recognized

StemData relaunch

Global Stem Cells Group has announced the relaunch of its StemData cloud-based electronic medical record system specifically designed for regenerative medicine practitioners.

MIAMI, Nov. 29, 2017—Global Stem Cells Group, a world leader in stem cell and regenerative medicine, has announced the relaunch of its StemData software, the first cloud-based electronic medical record system specifically designed for regenerative medicine practitioners.

The StemData system, initially launched in September 2016, is a customized software program for physicians who operate a regenerative medicine practice. The StemData software empowers physicians to follow patients throughout their treatment schedules. The StemData program comes programmed with the latest point-of-care regenerative medicine protocols and follow-up procedures to make it easy for stem cell patients to schedule appointments by phone, and for practitioners to document patient progress and gather important data to establish the safety and efficacy of stem cell treatments in the physician’s office environment.

The StemData system app is marketed exclusively through Global Stem Cells Group and will be provided free of charge to affiliate physicians in the Stem Cell Center network.

StemData’s cloud-based, server-less solution is accessible via web, iPad, iPhone, Google Glass and Apple Watch. Global Stem Cells Group has utilized the development of the latest electronic medical record (EMR) systems to bring intelligent EMR technology to regenerative medicine specialists.

The StemData app helps regenerative medicine practitioners increase efficiencies in their medical practices while improving both treatment and business outcomes. The app will intuitively adapt to each individual practitioner’s unique practice preferences.

To learn more about GSCG’s StemData solution, visit http://www.stemdata.org, email info@stemcellsgroup.com, or call +1305 560 5337.

About Global Stem Cells Group:

stemdata relaunch


Global Stem Cells Group
(GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global Stem Cell Group’s aim is to be the largest recognized stem cell and regenerative medicine network in the world.

stemdata relaunch

Aesthetic Polyclinic Abu Dhabi

 

 

 

 

 

Aesthetic Polyclinic Abu Dhabi

Global Stem Cells Group has named Aesthetic Polyclinic in Abu Dhabi, UAE, exclusive representative for GSCG in that city.

MIAMI, Nov. 9, 2017—Global Stem Cells Group (GSCG), a world leader in stem cell and regenerative medicine, has added Aesthetic Polyclinic to its worldwide regenerative medicine network, naming it the exclusive representative for GSCG in Abu Dhabi.

This new alliance is part of Global Stem Cells Group’s worldwide expansion of its clinical presence, partnering with qualified physicians experienced in stem cell therapies to open new clinics and utilize GSCG stem cell products and protocols in patient treatments. To date, GSCG has established similar alliances in 32 cities worldwide.

Aesthetic Polyclinic will provide advanced stem cell protocols and state-of-the-art techniques in stem cell therapies to patients from around the world. Aesthetic Polyclinic is GSCG’ fourth clinical presence in the Middle East, including Morocco, Iraq, and Pakistan.

Aesthetic Polyclinic specializes in plastic surgery, aesthetic medicine, dermatology, and general and cosmetic dentistry. The alliance with GSCG will add the benefits of stem cell applications for aesthetic and anti-aging treatments to the organization’s catalog of patient services. According to Sela Al Asadi, Managing Director for Aesthetic Polyclinic, the alliance is ideally suited to both organizations’ mission.

“Like Global Stem Cells Group, we are committed to meeting the growing needs of our clients and patients, and we continuously search for and adopt the latest medical technology and services,” Al Asadi says. “Our staff of committed, efficient, and customer-centric professionals is excited to represent Global Stem Cells Group and offer the benefits of their regenerative medicine products and protocols to our patients.”

Global Stem Cells Group provides stem cell treatments for a variety of conditions, diseases, and aesthetic treatments at facilities worldwide. The new facility will have an international staff that is experienced in administering the leading cellular therapies available.

Global Stem Cells Group’s Abu Dhabi clinic is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. GSCG clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.

Global Stem Cells Group is committed to providing the highest standards of services and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

To learn more about Global Stem Cells Group, visit the GSCG website,  email info@stemcellsgroup.com, or call +1305 560 533

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global Stem Cell Group’s aim is to be the largest recognized stem cell and regenerative medicine network in the world.

About Aesthetic Polyclinic

Aesthetic Polyclinic has been serving the residents of Abu Dhabi and Al Ain since 2000, providing world-class aesthetic services including plastic surgery dermatology, IPL hair removal, cosmetic and general dentistry, weight loss and body treatments, and specialized skin care.

One of Abu Dhabi’s top healthcare clinics, Aesthetic Polyclinic values the distinctly individual nature of all its clients and patients and prides itself in delivering quality customer service through customer focus, innovation, cutting-edge technology, and a commitment to excellence.

Formerly Aesthetic Skincare, it became Aesthetic Polyclinic in 2009 upon introducing dermatology and plastic surgery services. In 2013, the organization expanded its medical services with a brand new, state-of-the-art dedicated medical building and introducing dental and orthodontic services.

###

Aesthetic Polyclinic

 

XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery

 

 

 

 

 

 

 

The International Society for Stem Cell Application (ISSCA), and Global Stem Cells Group (GSCG) will sponsor the XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery Obesity. ISSCA and GSCG will launch their new online regenerative medicine training course, and will also launch a new adipose stem cell isolation kit, STEMPIA, at the event.

XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery .                   XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery


MIAMI, Nov. 9, 2017— The International Society for Stem Cell Application (ISSCA), a global leader in promoting education and setting standards in regenerative medicine, in collaboration with and Global Stem Cells Group (GSCG) will sponsor the XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery and Obesity Nov. 30 – Dec. 3, 2017, in Mexico City.

Hosted by the Institute of Higher Studies in Medicine (IESM), the annual International Congress is among the largest and most well-attended aesthetic medicine events in Ibero-America. More than 1,000 physicians from around the world are expected to attend. This year’s speaker lineup includes a renowned group of professionals in the field of regenerative medicine.

ISSCA and GSCG plan to leverage the large gathering of regenerative medicine and healthcare professionals at the International Congress to launch the newest cutting-edge online regenerative medicine training course in collaboration with Stem Cell Training, Inc.

The new virtual regenerative medicine training course is designed to instruct qualified physicians in the theoretical and practical protocols necessary to effectively and expertly administer regenerative medicine procedures to their patients. Training includes instructions for harvesting and isolating stem cells. The online training program positions physicians to provide stem cell procedures in their existing practice or open a stem cell center practice and join ISSCA’s international network of stem cell specialists.

In addition, the organizations will launch STEMPIA, a new adipose-derived stem call kit. The kit provides two specially designed tubes to isolate and concentrate adipose tissue-derived stromal vascular fraction (SVF). STEMPIA offers an easier, more effective, and shorter process for SVF isolation while maintaining high viability rates. STEMPIA uses less consumables and tools compared to manual SVF isolation processes, saving both costs and time in the SVF isolation process.

ISSCA, and GSCG will also be conducting a two-day, intensive regenerative medicine certification course for qualified physicians in Mexico City following the congress. Attendees will gain hand-on training and learn how to harvest and isolate stem cells, and expertly administer stem cell treatments to patients.. Upon completing the course, participants will receive certification and will be able to use their skills to treat patients in their practice, and for career advancement.

Fiesta Americana Reforma is the conference venue and headquarters. Visit the hotel data website page for location and additional information.

To learn more about the International Conference, visit the conference website email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s aim is to be the largest recognized stem cell and regenerative medicine network in the world.

###

XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery Obesity

regenerative-medicine-certification-training

 

 

 

 

 

 

 

The International Association for Stem Cell Application (ISSCA) will be conducting a regenerative medicine certification course for physicians in Buenos Aires Nov. 26-27, 2017. The two-day intensive training course teaches trainees extraction, isolation, and application of PRP, adipose, and bone marrow stem cells.

 

regenerative medicine certification training

MIAMI, Nov. 9, 2017— The International Society for Stem Cell Application (ISSCA), a global leader in regenerative medicine training, has announced plans to conduct regenerative medicine certification training for physicians in Buenos Aires, Argentina November 26 – 27, 2017.

The ISSCA training course, available to qualified physicians interested in adding regenerative medicine to their practice procedures, provides hands-on, practical instruction under the guidance of trained medical experts in a highly visual, interactive, and clinical learning environment.

.ISSCA’s medical professionals teach reintegration and procedural techniques on live patients using different protocols for isolating stem cells. Trainees will participate in different medical cases under the supervision of trained specialists.

This hands-on stem cell training course provides each participant with a live demonstration of the extraction, isolation, and application of PRP, adipose, and bone marrow stem cells. Techniques and materials used in the course, along with high-resolution, step-by-step procedure videos are provided for the participating physician’s future use and reference.

Led by ISSCA’s established team of skilled practitioners, this course is designed specifically to provide personalized instruction. Seats for each course are limited to 8-10 trainees, not only to suit each participant’s individual training needs but also to allow for professional networking.

Participants who complete the training will receive certification that documents their participation in and completion of the training, their and their knowledge and skills in the field of regenerative medicine. Certification candidates are required to provide proof of prior medical training and experience, and successfully complete a written as well as an oral/practical exam. Certification confirms a physician’s expertise in regenerative medicine.

​Certification procedures and requirements are key to the integrity of regenerative medicine. They furnish a reputable credential that is essential not only for patients to see, but also to a physician’s practice.

The Buenos Aires certification training course will mark the 11th event ISSCA has sponsored and hosted thus far in 2017. The organization is working to position itself as a reference point for regenerative medical practitioners worldwide. With a presence in more than 25 countries, physicians interested in certification can check for an ISSCA training course near them by visiting the https://www.stemcelltraining.net/ website, email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

.                                                                                                               ###
Regenerative medicine certification training